The turn of spring and summer has brought us a string of good tidings and great joy. Mr. Zhigang Tian, a member of the Chinese Academy of Engineering, professor of the University of Science and Technology of China and chairman of NK Celltech, was elected to the Academia Europaea 2022 (clinical & veterinary science) for his outstanding contribution to international clinical translational medicine.

Zhigang Tian
MD & PhD

Member of Chinese Academy of Engineering 
 Member of Academia Europaea (The Academy of Europe).
Professor of University of Science & Technology of China (USTC)

The list of newly elected members of the Academia Europaea 2022 is published on its official website (www.ae-info.org). The Academia includes members mainly from European countries, representing the highest scientific level and academic status in the humanities and natural sciences in Europe. The Academia has approximately 5,500 members, including 90 Nobel Laureates, many of whom were awarded the Nobel Prize only after being elected to the Academia.

As the chairman of NK CellTech, Dr. Zhigang Tian has been leading the R&D team to delve into the development of cell therapies, forming a distinctive edge in NK cell-based cellular therapies and reaching a cutting-edge level on a global scale.

NK CellTech is a biotech company focusing on the discovery and development of innovative technology of NK cell therapy. The R&D team has over 30 years of experiences in the research and clinical practice of NK cells, which dedicates NK CellTech to become an international leading company in cellular immunotherapy. With our ABCDE-NK® platform (Allogeneic, Blood-derived, Cryopreserved Off-The-Shelf, Designed Genetically On Demand, Expanded to Clinical Scale) and SynNK™ platform (genetic logic gate technology of synthetic immunology), NK CellTech will deliver the innovative cellular drugs to precisely target broaden spectrum of tumors and harness the adaptivity to tumor immune microenvironment (TIME), leading to the consistent development of “intelligent” NK cell products to fulfil the unmet clinical needs of cancer patients.